Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | HRH2 | P25021 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11068165 | 0.95 | SMN1; SMN2 (0.52) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11010882 | 0.93 | SMN1; SMN2 (0.55) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11106320 | 0.93 | SMN1; SMN2 (0.55) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| Lavoltidine SCHEMBL30095469 | 0.93 | SMN1; SMN2 (0.55) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| Lavoltidine SCHEMBL1142 | 0.93 | SMN1; SMN2 (0.55) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10754400 | 0.90 | HRH2 (0.54) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10751306 | 0.90 | SMN1; SMN2 (0.52) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10749102 | 0.90 | HRH2 (0.53) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10750433 | 0.89 | HRH2 (0.56) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11056248 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230349922-A1 | H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer | UNIVERSITÉ DE STRASBOURG (FR) | 2023-11-02 | — | — | US | disclosed |
| EP-4196793-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | Université de Strasbourg (FR) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022034121-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | UNIVERSITÉ DE STRASBOURG (FR) | 2022-02-17 | — | — | WO | disclosed |
| US-8277782-B2 | Antiinflammatory agent, metalloproteinase inhibitor, anti-oxidant and modifier of cell redox status, vitamins, inhibitor of activation of nuclear factor kappa beta | THE PROCTER & GAMBLE COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| EP-1294367-B1 | ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT | PROCTER & GAMBLE (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20060193790-A1 | Promoting whole body health | THE PROCTER & GAMBLE COMPANY | 2006-08-31 | — | — | US | disclosed |
| US-20050042283-A1 | Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer | UNIVERSITY OF MASSACHUSETTS (US) | 2005-02-24 | — | — | US | disclosed |
| WO-2005007107-A2 | HISTAMINE AND CCK2/GASTRIN RECEPTOR BLOCKADE IN THE TREATMENT OF ACID-PEPTIC DISEASE AND CANCER | UNIVERSITY OF MASSACHUSETTS (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1294367-A2 | ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT | The Procter & Gamble Company (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002002096-A2 | ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
| US-5364616-A | Use of H-2 antagonists for treatment of gingivitis | THE PROCTER & GAMBLE COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| US-5294433-A | Dentistry | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-15 | — | — | US | disclosed |
| WO-1993020815-A1 | USE OF H-2 ANTAGONISTS FOR TREATMENT OF GINGIVITIS | THE PROCTER & GAMBLE COMPANY (US) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060193790-A1 | Promoting whole body health | IFNG, TNF, TLR6 | SMN1; SMN2 3189/4885TP53 2738/4885CYP1A2 2115/4885 |
| US-20050042283-A1 | Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer | HRH2, CCKBR, GRPR | SMN1; SMN2 3838/4885TP53 2468/4885CYP1A2 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.